About Sedia Biosciences
Sedia Biosciences is a company based in Portland (United States) founded in 2009.. Sedia Biosciences has raised $285 thousand across 7 funding rounds from investors including HHS, Cascadia Venture Forum and NIH SBIR/STTR. The company has 33 employees as of December 31, 2022. Sedia Biosciences has completed 1 acquisition, including Floragenex. Sedia Biosciences offers products and services including SEDIA HIV-1 LAg-Avidity EIA, Asanté HIV-1 Rapid Recency, Asanté HIV-1/2 Oral Self-Test, Asanté Specimen Collection Devices, and Sedia Custom Testing Services. Sedia Biosciences operates in a competitive market with competitors including Souzhou Ribo Life Science, PathoQuest, Quantalife, Chembio and Senzo, among others.
- Headquarter Portland, United States
- Employees 33 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sedia Biosciences Corp.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$285 K (USD)
in 7 rounds
-
Latest Funding Round
-
Investors
HHS
& 3 more
-
Employee Count
33
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sedia Biosciences
Sedia Biosciences offers a comprehensive portfolio of products and services, including SEDIA HIV-1 LAg-Avidity EIA, Asanté HIV-1 Rapid Recency, Asanté HIV-1/2 Oral Self-Test, Asanté Specimen Collection Devices, and Sedia Custom Testing Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enzyme immunoassay to detect recent HIV infections for surveillance
Assay for identifying recent HIV infections using various specimens
Oral fluid test for HIV detection in point-of-care settings
Devices for stabilizing and transporting clinical specimens remotely
Solutions for genomic analysis in human and animal systems
Unlock access to complete
Leadership Team
6 people
Sales and Marketing
2 people
Software Development Team
1 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Sedia Biosciences
Sedia Biosciences has successfully raised a total of $285K across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Last Round
-
First Round
First Round
(01 Jul 2011)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2017 | Amount | Seed - Sedia Biosciences | Valuation |
investors |
|
| Aug, 2014 | Amount | Grant - Sedia Biosciences | Valuation |
investors |
|
| Aug, 2014 | Amount | Grant - Sedia Biosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sedia Biosciences
Sedia Biosciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Cascadia Venture Forum and NIH SBIR/STTR. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sedia Biosciences
Sedia Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Floragenex. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Genomic-based products and services are provided for research purposes.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Sedia Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sedia Biosciences Comparisons
Competitors of Sedia Biosciences
Sedia Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Souzhou Ribo Life Science, PathoQuest, Quantalife, Chembio and Senzo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| domain | founded_year | HQ Location |
Next-generation sequencing is provided for microbiology testing applications.
|
|
| domain | founded_year | HQ Location |
Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
|
|
| domain | founded_year | HQ Location |
Proprietary immunoassay platform is utilized for infectious disease diagnostics.
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic devices for infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biopreservation platform for mammalian cells and biologics is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sedia Biosciences
Frequently Asked Questions about Sedia Biosciences
When was Sedia Biosciences founded?
Sedia Biosciences was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Where is Sedia Biosciences located?
Sedia Biosciences is headquartered in Portland, United States. It is registered at Portland, Oregon, United States.
Is Sedia Biosciences a funded company?
Sedia Biosciences is a funded company, having raised a total of $285K across 7 funding rounds to date. The company's 1st funding round was a Grant of $1.99M, raised on Jul 01, 2011.
How many employees does Sedia Biosciences have?
As of Dec 31, 2022, the latest employee count at Sedia Biosciences is 33.
What does Sedia Biosciences do?
Sedia Biosciences was founded in 2009 in Portland, United States, within the biotechnology sector focused on diagnostics. Point-of-care assays and immunoassays for HIV detection are developed, including the research-use HIV Incidence Assays for epidemiological surveillance and the Asante line of rapid oral tests as alternatives to ELISA methods. Specimen collection devices are also produced to support testing operations.
Who are the top competitors of Sedia Biosciences?
Sedia Biosciences's top competitors include Souzhou Ribo Life Science, Chembio and Quantalife.
What products or services does Sedia Biosciences offer?
Sedia Biosciences offers SEDIA HIV-1 LAg-Avidity EIA, Asanté HIV-1 Rapid Recency, Asanté HIV-1/2 Oral Self-Test, Asanté Specimen Collection Devices, and Sedia Custom Testing Services.
How many acquisitions has Sedia Biosciences made?
Sedia Biosciences has made 1 acquisition, including Floragenex.
Who are Sedia Biosciences's investors?
Sedia Biosciences has 4 investors. Key investors include HHS, Cascadia Venture Forum, NIH SBIR/STTR, and NIAID.